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Background: Endometrial regenerative cells (ERCs) are mesenchymal-like stem cells that can be non-invasively
obtained from menstrual blood and are easily grown /generated at a large scale without tumorigenesis. We previously
reported that ERCs exhibit unique immunoregulatory properties in vitro, however their immunosuppressive potential in
protecting the colon from colitis has not been investigated. The present study was undertaken to determine the
efficacy of ERCs in mediating immunomodulatory functions against colitis.
Methods: Colitis was induced by 4% dextran-sulfate-sodium (DSS, in drinking water) in BALB/c mice for 7 days. ERCs were
cultured from healthy female menstrual blood, and injected (1 million/mouse/day, i.v.) into mice on days 2, 5, and 8
following colitis induction. Colonic and splenic tissues were collected on day 14 post-DSS-induction. Clinical signs, disease
activity index (DAI), pathological and immunohistological changes, cytokine profiles and cell populations were evaluated.
Results: DSS-induced mice in untreated group developed severe colitis, characterized by body-weight loss, bloody stool,
diarrhea, mucosal ulceration and colon shortening, as well as pathological changes of intra-colon cell infiltrations of
neutrophils and Mac-1 positive cells. Notably, ERCs attenuated colitis with significantly reduced DAI, decreased levels of
intra-colon IL-2 and TNF-α, but increased expressions of IL-4 and IL-10. Compared with those of untreated colitis mice,
splenic dendritic cells isolated from ERC-treated mice exhibited significantly decreased MHC-II expression.
ERC-treated mice also demonstrated much less CD3+CD25+ active T cell and CD3+CD8+ T cell population and
significantly higher level of CD4+CD25+Foxp3+ Treg cells.
Conclusions: This study demonstrated novel anti-inflammatory and immunosuppressive effects of ERCs in attenuating
colitis in mice, and suggested that the unique features of ERCs make them a promising therapeutic tool for the
treatment of ulcerative colitis.
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Ulcerative colitis (UC) is a form of inflammatory bowel
disease (IBD), characterized by the chronic, relapsing,
non-specific inflammation of the colon and rectum. The
inflammatory process in UC is confined to the mucosa.
In contrast, Crohn’s disease (CD), another form of IBD, is
characterized by segmental transmural mucosal inflamma-
tion and granulomatous changes, which affects any part
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unless otherwise stated.perianal region [1]. Currently, UC has demonstrated
high prevalence and incidence in the western countries,
and these figures are rapidly rising in other parts of the
world such as China during the past decades [2]. Despite
extensive research, the definite cause of UC remains
unclear. The general consensus appears to be that UC
is related to individual genetic susceptibility, environmental
risk factors or exposures, alterations of the gut microbiome
and a deregulated immune system [3,4]. Conventional
treatment for UC includes anti-inflammatory drugs,
immunosuppressive agents, biological therapy and even
colectomy [5]. However, these therapies often fail to ob-
tain satisfactory results or even make the patients lose theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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involves side effects resulting in many complications,
such as osteoporosis, metabolism disorders, cushingoid
features, infections, gastroduodenal mucosal injury and
impaired wound healing [6-8]. In this view, searching
for a novel therapeutic strategy to treat UC is needed
[9].
In the recent years, stem cell-based therapy as a promis-
ing alternative solution draws considerable attention for
UC treatment. As an attractive candidate in cell therapy,
mesenchymal stem cells (MSCs), a group of self-renewing,
pluripotent stromal cells that can differentiate into mul-
tiple lineages [10], can promote tissue repair and wound
healing in UC [11,12]. In the meantime, MSCs possess im-
munomodulatory and anti-inflammatory properties. These
cells can interfere with the function of certain immune
cells such as DCs, natural killer cells (NKs), T cells and B
cells by means of cell-to-cell interaction and soluble factor
secretion [13-16]. Moreover, MSCs are relatively immune
privileged and capable of evasion from allo-reactive im-
mune response, due to the low expression of MHC-II and
co-stimulatory molecules on the surface, which means
these cells are transplantable between HLA-incompatible
persons [14,17]. MSCs can be obtained from many differ-
ent types of tissues in the body, such as bone marrow and
adipose tissue. Among all cell types, bone marrow-derived
MSCs are the best characterized population and have
been proven to be effective in experimental UC models
[12,18,19]. However, there exist some pitfalls of these
sources, such as the invasive accessible method and
related complications, less availability and limited pro-
liferation capacity. Therefore, in addition to MSCs,
searching for a new source of regenerative cells is
warranted.
ERCs, a new mesenchymal-like cell population isolated
from the menstrual blood, which present great regen-
erative potential during menstruation, satisfy the critical
criteria of MSCs but overcome the hurdles of other
conventional sources. Apart from the ease of abstraction,
ERCs are marked by considerable expandability while
maintaining karyotypic normality and differentiation cap-
acity [20]. We and others have demonstrated that ERCs
effectively prevent critical limb ischemia in mice, and most
importantly, the therapeutic effect of ERC was observed
despite the use of human cells in a xenogeneic animal
model [21]. Furthermore, the efficacy of ERCs has also
been tested in other experimental models of stroke
[22] and heart failure [23]. However, whether ERCs
could be feasible to simultaneously repair the damaged
tissue and rectify the abnormal immune system of UC
is unclear [20,21]. In this study, we investigated the
anti-inflammatory and immunoregulatory properties
of ERCs in DSS-induced colitis using systemic infusion
of ERCs in a mouse model.Methods
Animals
Eight-week-old male BALB/c mice (Aoyide Co., Tianjin,
China) weighing 18 to 20 g were housed under conven-
tional experimental environment with 12-hour light–dark
cycle in the Animal Care Facility, Tianjin General Surgery
Institute. The mice had a free access to commercial
standard mouse diet and water. All experiments were
conducted in accordance with the protocols approved
by the Animal Care and Use Committee of Tianjin
Medical University (China) according to the Chinese
Council on Animal Care guidelines.
Preparation of ERCs for in vivo treatment
According to Naoko Hida et al., ERCs were collected
from approximately 10 ml of menstrual blood of eight
women (20–30 years old) on the first day of menstru-
ation after informed consent was obtained. The samples
were suspended in Dulbecco’s modified Eagle’s medium
(DMEM) high glucose supplemented with 10% fetal
bovine serum (FBS), and split into two 10-cm dishes. The
estimated adherent cell number at the start of culture was
approximately 1 × 107 [24].
Experiment design
DSS-induced colitis model was established in mice ac-
cording to Kihara, N et al. [25]. Twenty four BALB/c mice
were randomly assigned to three groups, each consisting
of eight animals: Group 1, naive mice drinking no-DSS
water for 14 days, as normal control. Group 2, colitis in
mice was induced by drinking 4% DSS for 7 days, followed
by another 7 days consumption of normal water, as un-
treated colitis control. Group 3, mice with DSS-induced
colitis were intravenously injected with ERCs (suspended
in phosphate buffered saline (PBS), 1 × 106/0.25 ml/mouse)
on day 2, 4, 6, 8, as the study group. The body weight, stool
consistency and characteristics of bloody stools of each
mouse, as well as the DAI were evaluated during experi-
ment. DAI was scored according to the following criteria
(a) body weight loss: 0 (no change); 1 (1-5%); 2 (5-10%); 3
(10-20%); and 4 (>20%). (b) Stool consistency or diarrhea:
0 (normal); 1 (some soft); 2 (soft); 3 (unformed/mild diar-
rhea); and 4 (severe watery diarrhea). Hemoccult positivity
and the presence of gross stool blood: 0 (negative fecal
occult blood); 1 (negative/positive fecal occult blood);
2 (certain positive fecal occult blood); 3 (visible rectal
bleeding); 4 (severe rectal bleeding). DAI is the sum
score of body weight loss, stool consistency and gross
bleeding, divided by 3. All mice were sacrificed on
day14 post DSS-induction (as a uniform time point)
for collection of spleen and colon samples and for the
comparison of experimental data between ERC treated
group and untreated group. The colon was excised
from the ileocecal junction to the anus, and the length
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colon sections were washed in cold physiological saline
solution and the colonic contents were removed. Half
of the colon samples was fixed in 10% formalin and
processed for paraffin embedding. The other part was
stored frozen at −80°C.
Histology
At necropsy, the colonic samples were fixed in 10% buff-
ered formaldehyde, embedded in paraffin and sectioned
into 5 μm for haematoxylin and eosin staining. As previ-
ously described, the microscopic sections were examined
in a blinded fashion by a pathologist. Histological changes
were scored according to the following criteria (a) in-
flammation severity: 0 (none), 1 (slight), 2 (moderate), 3
(severe); (b) depth of injury: 0 (none), 1 (mucosal), 2
(mucosal and submucosal), 3 (transmural); (c) crypt
damage: 0 (none), 1 (basal 1/3 damage), 2 (basal 2/3
damage), 3 (crypt lost, only surface epithelium intact), 4
(entire crypt and epithelium lost); (d) percent involvement:
1 (1%-25%), 2 (26%-50%), 3 (51%-75%), 4 (76%-100%). Each
parameter score was multiplied by a factor reflecting
percent involvement of the intestinal wall and summed
to obtain a histopathology score. The minimal score was
0 and the maximal score was 40 [26].
Immunohistochemistry
To examine the protein expression levels of myeloperoxi-
dase (MPO) and Mac-1 (CD11b) in the colon, the paraffin
embedded colon specimens were cut into 5 μm, followed
by deparaffined and rehydrated. Endogenous peroxides
were blocked with 3%H2O2, and antigen retrieval was
processed by heating in microwave. After enclosed by 5%
bovine serum albumin (BSA), the specimens were stained
according to the instructions of Strept Avidin-Biotin
Complex (SABC) kit. The primary antigens were MPO
goat anti-mouse antibody and Mac-1 goat anti-mouse
antibody, and the secondary antigens were biotinylated
goat anti-rabbit antigen. The negative control group
was administered with PBS instead of primary antigen
and stored frozen at 4°C overnight. The sections were
graded by two blinded investigators to determine the
immunoreactivity score according to the following criteria:
(a) signal intensity: 0 (no staining), 1 (weak staining), 2
(moderate staining), or 3 (strong staining) and (b) percent-
age of positive cells in the tissue: 0 (0%), 1 (1%–10%), 2
(11%–25%), 3 (26%–50%), 4 (51%–75%), or 5 (76%–100%).
Immunoreactivity score was calculated by multiplying the
score for the percentage of positive cells by the intensity
score (range of 0 to 15) [27].
Real-time quantitative PCR
The gene transcriptional levels of IL-2, TNF-α, IL-4, IL-10
in colon tissues, and the gene transcriptional levels ofIL-2, TNF-α in the spleen were determined by florescent
real-time quantitative RT-PCR using real-time PCR in-
strument (MJ Research Inc., USA). The PCR primers
were designed as follows: IL-2, upstream 5′-GGCAT
GTTCTGGATTTGACTC-3′, downstream 5′-CTCATC








To test the cell count of CD3+CD25+ cells,CD3+CD8+
cells, CD4+CD25+ Foxp3+Tregs, CD11c+MHC-II+ DCs
in the spleen, splenic single-cell suspensions were pre-
pared with the final concentration of 1 × 107/ml before
immunofluorescent staining. Fluorescent antibodies,
including CD3ε-FITC, CD8a-PerCP, CD4-PE, CD25-APC,
Foxp3+-FITC, CD11c-PE, MHC-II-FITC (Miltenyi Biotec,
Germany), were added to the suspensions respectively.
After incubation for 10mins, cells were washed in PBS,
followed by centrifuging for 10 mins and fixation in 1%
polyoxymethylene for more than 2 hours. Cells were ana-
lyzed using flow cytometry.
Statistical analysis
Statistical analysis was performed in SPSS version 17.0
software (SPSS Inc., Chicago, USA) and the experimental
data were presented as mean ± SD. The DAI scores, flow
cytometric data, histology/immunohistochemistry scores
and RT-PCR results were compared among groups by
using one-way ANOVA. Differences with p values less
than 0.05 were considered significant.
Results
ERCs ameliorate the symptoms of DSS-induced colitis
To determine the efficacy of ERCs in attenuation of colitis,
we have evaluated clinical symptoms of DSS-induced col-
itis in mice. We found that untreated mice with colitis ex-
hibited body weight loss, bloody loose stool and lethargy.
In contrast, ERC-treated mice showed less body weight
loss, firmer stool, as well as an increase in food and water
consumption, indicating that the substantial wasting
conditions caused by colitis were ameliorated by ERC
treatment. Meanwhile, the incidence of bloody stool
was clearly prevented in the ERC treated group as
compared to that of the untreated group (Figure 1A).
In addition, DAI, scored daily to assess the colitis ac-
tivity, in ERC treated group was slightly higher than
that of the normal group, however it was much lower than
of the untreated group on day 14 post-colitis induction
(*p < 0.05, Figure 1B).
BA












Figure 1 ERCs attenuate the development of experimental
colitis represented by DAI. A) Representative photo showing
bloody stool in untreated colitis mice as compared to ERC-treated
colitis mice. B) DAI, scored daily to assess the colitis activity, in
different groups (n = 8 mice per group). *p < 0.05, ERC-treated group
vs. untreated group on day 14 post-colitis induction.
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colitis mice
Macroscopically, on day 14 post-colitis induction, mice
in the untreated colitis group exhibited inflammation
mainly in the distal colon with distal part constrictive
and proximal part dilated. The lesions were character-
ized by mucosal hyperemia and ulceration. In the ERC
treated group, obvious bowel dilation was not observed,
and the length of colon was significantly longer than that
of untreated colitis mice (*p < 0.05, Figure 2A). Mean-
while, mucosal hyperemia and edema were relieved, and
the ulceration was almost healed (data not shown). Micro-
scopically, in the colon collected from normal mice, intact
epithelium and crypts were observed, with intestinal
glands arranged in order, abundant goblet cells and few in-
flammatory cell infiltration. The pathology in untreated
group showed severe inflammatory changes, characterized
by damaged epithelium and crypts structure, glandular
disorder, little goblet cell regeneration, and massive
inflammatory cell infiltration into the mucosa and
submucosa (Figure 2B). Whereas in the ERC treated
group, mouse colon presented an improved structure
of epithelium and crypts, with much less inflammatorycell infiltration but more regenerative goblet cells. In
addition, the histopathological scores in ERC-treated
group were significantly lower than that of untreated
group (*p < 0.05), suggesting the less injury in the colon
following ERC treatment.ERCs reduce intra-colon neutrophil and Mac-1 positive
cell infiltration in the colitis mice
To investigate the effects of ERCs on attenuation of in-
flammatory cell infiltration in the colitis mice, we have
detected and compared intra-colon MPO (a biomarker
for activated neutrophils) and Mac-1 positive cell infil-
tration in both untreated and ERC-treated colitis mice.
As compared to untreated colitis mice, the levels of
MPO positive neutrophils and Mac-1 positive cells, which
include macrophages, NK cells and granulocytes were sig-
nificantly reduced in the colon following ERCs treatment
(*p < 0.05) (Figure 3).ERCs attenuate the transcriptional levels of cytokines in
the colitis mice
To determine whether ERC treatment would affect the
transcriptional levels of cytokines, we have measured
intra-colon expression of IL-2, IL-4, IL-10 and TNF-α by
real-time PCR. As shown in Figure 4A-D, there were sig-
nificant increases on IL-2 and TNF-α levels in colon of
untreated colitis mice as compared with those of the
normal mice and the ERC-treated colitis mice (#p < 0.01).
In addition, both IL-4 and IL-10 were notably up-regulated
in colon of the ERC treated group when compared with
those of untreated group (*p < 0.01). In order to determine
the systemic effects of ERC treatment on the transcriptional
levels of cytokines, we have examined the levels of splenic
IL-2 and TNF-α mRNA expression by real-time PCR. Fol-
lowing the transplantation of ERCs, the levels of these
pro-inflammatory cytokines were significantly decreased
(*p < 0.01), when compared with those of the untreated
group (Figure 4E).ERC treatment modulate the number of immune cells in
colitis mice
To further investigate the immunomodulatory function
of ERCs in attenuation of colitis, the splenic immune cell
populations were evaluated on day 14 post-colitis induc-
tion. We found that the populations of CD3+CD25+ ac-
tive T cells, CD3+CD8+ T cells and CD11c+MHC-II+
DCs were significantly reduced by ERC treatment as
compared to those of untreated colitis mice (*p < 0.01,
Figure 5A, B, D). In addition, there was much higher
level of CD4+CD25+Foxp3+ Tregs in ERC treated mice
than that of untreated colitis mice and normal mice













































Figure 2 ERCs attenuate the pathological changes of experimental colitis. A) The length of mouse colon from normal, untreated and
ERC-treated groups. *p < 0.05, ERC-treated group vs. untreated group. B) Representative photomicrographs (200×, haemotoxylin and eosin
staining) of histological sections of colon from normal, untreated and ERC-treated groups. Overall histology scores in the normal, untreated and
ERC-treated groups (n = 8 mice per group). *p < 0.05, ERC-treated group vs. untreated group.
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Lately, cell therapy has been reported to be effective in
the treatment of IBD, including UC and CD. MSCs,
which can be obtained from many tissues, such as bone
marrow and adipose tissue, are considered as promising
candidates for cell therapy to treat UC. Currently, there
are a few data on the therapeutic effects of ERCs, a novel
population of stem cells acquired from menstrual blood.
Other than the known advantages of MSCs, including
proliferation and differentiation capacity, immunomod-
ulatory property and immunoprivilege, ERCs possess
additional outstanding merits, such as 1) abundant
availability, 2) easy and painless extraction and isolation,
3) higher proliferation rate, 4) relative unlimited expand-
ability without karyotypic or functional abnormality, 5)
differentiation potential into more lineages [28]. In the
current experiment, DSS–induced colitis model exhibited
similar symptoms of UC patients, which include bodyweight loss, bloody stool and shortening of the colon. In
the experimental colitis model, higher DAI scores were
recorded which resembled the active stage. Under the
microscopy, damaged epithelium and crypts were ob-
served, as well as inflammatory cell infiltration which
was confirmed by increased expression levels of MPO and
Mac-1. Administration of ERCs ameliorated the symp-
toms, attenuated the microscopic pathological changes
and the inflammatory cell infiltration, reflected by the re-
duced DAI scores and histological scores, respectively.
It is well known that UC is associated with abnormal
immune system, where altered cell populations and cyto-
kine secretion profiles play an important role [29]. In
this study, to evaluate the related mechanism of ERCs,
we have focused on their anti-inflammatory and immu-
nomodulatory properties in attenuation of colitis. The
results suggest that ERCs may have regulatory functions
































































Figure 3 ERCs reduce intra-colon neutrophil and Mac-1 positive cell infiltration in the colitis mice. The levels of intra-colon MPO and
Mac-1 positive cell infiltration in normal, untreated and ERC-treated groups. Magnification 400×. (n = 8 mice per group) *p < 0.05, ERC-treated
group vs. untreated group.
Lv et al. Journal of Translational Medicine 2014, 12:344 Page 6 of 11
http://www.translational-medicine.com/content/12/1/344cells, CD3+CD8+ T cells, CD4+CD25+ Foxp3+ Tregs and
CD11c+MHC-II+ DCs in the colitis mice.
DCs are professional antigen-presenting cells which
can take up antigens and present the processed antigens
to other immune cells. The intestinal DCs have been in-
vestigated extensively. It was reported that UC is associ-
ated with the disruption of the delicate balance between
the immunogenicity against invading pathogens and toler-
ance of the commensal microbiota, which is maintained
by intestinal DCs at steady state [30]. In the current study,
we have evaluated the number of splenic DCs distant from
the intestine, and observed that the CD11c+MHC-II+ DCs
increased significantly in the untreated colitis group. This
was supported by previous reports, which stated that
MSCs are capable of inhibiting the differentiation of
monocytes into DCs [15,31-33]. This result suggests that
ERCs probably reduce the cell number of DCs in the
spleen, and exert immunomodulatory effects to control
the development of colitis. Moreover, it was reported that
splenic DCs may contribute to the systemic inflammation
component, our finding further indicated the systemic
therapeutic effects of ERCs [34].As compared to untreated group, CD3+CD25+ active T
cells were significantly downregulated after ERC treat-
ment, indicating ERC might reduce T cell activation. To
investigate the effects of ERCs on different T lymphocyte
subsets, we have also measured the levels of CD4+CD25+
Foxp3+ Tregs and CD3+CD8+ T cells in different groups.
CD4+CD25+Foxp3+ Tregs account for 5%-10% of
the CD4+ T cell panel in healthy human and mice,
which are sufficient to play an important role in the
maintenance of immune homeostasis and the limitation
of autoimmune disease [35]. It has been shown that
CD4+CD25+Foxp3+-deficient mice are hyperactive to
intestinal commensal flora and would develop IBD trig-
gered by infection. Transferring of CD4+CD25+Foxp3+
Tregs into immune deficient mice under aseptic conditions
was capable of preventing or even reversing the develop-
ment of IBD [36-38]. Similarly, our results demonstrated
that CD4+CD25+Foxp3+ Tregs decreased significantly in
the untreated colitis mice as compared to that of normal
mice. However, the Treg population was markedly en-
hanced by intravenous injection of ERCs to the colitis
mice, indicating that ERCs increase Tregs which may be
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Figure 4 Effects of ERCs on the regulation of IL-2, TNF-α, IL-4 and IL-10 expressions in mice. The mRNA levels of IL-2, TNF-α, IL-4 and IL-10
were analyzed by real-time PCR. A&B) ERCs reduced IL-2 and TNF-α mRNA expression in colon tissues in DSS-induced colitis mice. (n = 8 mice
per group) #p < 0.01, untreated group vs. normal mice and the ERC-treated group. C&D) ERCs increased IL-4 and IL-10 mRNA expression in colon
tissues in DSS-induced colitis mice. E) ERCs reduced IL-2 and TNF-α mRNA expression in the spleen in DSS-induced colitis mice. (n = 8 mice per
group) *p < 0.01, ERC-treated group vs. untreated group.
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and maintenance of the immune tolerance, thereby lead-
ing to the attenuation of colitis.
Furthermore, CD3+CD8+ T cells are capable to bind to
the complex of MHC-Imolecules and antigens followed
by the destruction of the target cells. The role of CD3
+CD8+ T cells in the IBD remains unclear and controver-
sial. It was claimed that cell-mediated cytotoxicity contrib-
utes to the exacerbation and perpetuation of active IBD
[39]. According to some previous studies, antigen-specific
CD8+ T cells are capable to induce intestinal inflammation
triggered by epithelium-specific antigens which can be
controlled by antigen-specific Tregs under physiological
conditions [40]. The contribution of CD8+ T cell was con-
firmed by the in vivo monoclonal antibody depletion and
cell- transfer experiments [41]. In our study, untreated
colitis mice exhibited a high level of CD3+CD8+ T cells, in
which was significantly down-regulated by the treatment
of ERCs, suggesting that ERCs can down-regulate
CD3+CD8+ T cell level, thereby ameliorating the cytotox-
icity and correcting the dysfunctional immune system.This finding also indicated that, like MSCs, ERCs possess
some immunomodulatory properties which could sup-
press the activation and proliferation of T cells and inhibit
the differentiation of naïve CD8+ T cells into cytotoxic
effector cells [42].
The data from the current study also suggest that ERCs
could play a critical role in attenuating the pathogenesis of
colitis through modulating the cytokine profile. Previous
studies have revealed that the alterations of the cytokine
production disrupt the balance of the immune system and
have an impact on the pathogenesis of IBD [43-45]. Accu-
mulating evidence has shown that MSCs exert immuno-
modulatory properties on IBD by changing the cytokine
secretion profiles through paracrine [13,46]. Thus, the
present study was undertaken to determine whether ERCs
share the similar attribute of MSCs in amelioration of
colitis partially through regulating cytokine profiles in
this experimental model. It has been known that IL-2,
the product of the activated T cells, is necessary for the
proliferation and differentiation of naïve T cells into



























































































































Figure 5 ERCs modulate the levels of immune cells in the spleen of colitis mice. The levels of immune cells were analyzed by flow
cytometry in different groups. A) The level of CD3+CD25+ cells in the spleen from normal, untreated and ERC-treated groups. B) The level of
CD3+CD8+ cells in the spleen from normal, untreated and ERC-treated groups. C) The level of CD4+CD25+ Foxp3+ Tregs in the spleen from
normal, untreated and ERC-treated groups. D) The level of CD11c+MHC-II+ DCs in the spleen from normal, untreated and ERC-treated groups.
(n = 8 mice per group) *p < 0.01, ERC-treated group vs. untreated group.
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untreated colitis mice were significantly down-regulated
in ERC treated mice. This indicates that in the presence
of ERCs, the secretion of Th1 (e.g. IL-2) cytokine was
suppressed, which favors the shift of cytokine paradigm
from a Th1 to a Th2 production, and facilitates the
inhibition of the cell-mediated cytotoxity [48,49]. TNF-α,
as a pro-inflammatory factor generated mainly by macro-
phages, plays a central role in the pathogenesis of UC
[50]. The serum levels of TNF-α correlate with the clinical
activity of UC. As indicated by previous reports, TNF-α
blockers such as Infliximab are effective in the attenuation
of inflammation, as well as the induction and maintenance
of the long-term remission [51]. Our data showed
that ERCs down-regulate the transcriptional level of
TNF-α, suggesting its therapeutic benefits through
anti-inflammation mechanism.
Moreover, our results also showed significantly increased
transcriptional levels of IL-4 and IL-10 in the colon tissues
of ERC-treated colitis mice compared to untreated colitis
mice. As a result from the shift from Th1 to Th2 immune
response, ERCs could promote the secretion of IL-4
followed by down-regulating inflammatory mediators
such as TNF-α, IL-1 to exert anti-inflammatory and im-
munomodulatory effects. The increased level of IL-4
indicated a possible molecular therapeutic mechanism
of ERCs on the colitis mice, which is consistent with
previous findings that IL-4 has a protective function inintestinal tract of experimental colitis [52,53]. However,
the role of IL-4 in IBD remains controversial, as to be
either beneficial or detrimental in different experiment
conditions [44,54,55]. The variations may result from
the animal models, administration methods and differences
in assay systems. Thus, further investigations are needed to
clarify the role of IL-4 and to determine how ERCs exert
therapeutic effects on IL-4 in the colitis. In addition, IL-10
is a potent anti-inflammatory cytokine that inhibits antigen
presentation and the release of inflammatory factors [56].
IL-10-deficient mice are highly prone to chronic colitis and
genomically-controlled human IL-10 expression rescued
Il10−/− mice from Helicobacter-induced colitis [45,57]. We
found that ERC-treated mice had a dramatically increase in
the transcriptional level of IL-10 compared to that of
untreated mice. Therefore, we speculate that ERCs en-
hance the IL-10 level in the similar method reported
by previous studies that MSCs can secrete IL-10 and
promote the production of IL-10 by other antigen-
presenting cells to exert anti-inflammatory and immu-
nomodulatory effects [58,59].
Another intriguing feature of ERCs is their proliferative
potential. According to previous reports, bone marrow-
derived MSCs can effectively repair the injured tissues.
Khalil et al. demonstrated that implanted MSCs are cap-
able to induce the recovery of injured epithelium either
by differentiation into the endothelial cells or improved
angiogenesis [60]. Yujiro Hayashi et al. acclaimed that
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both in vitro and after implantation to exert reparative
effects in gastrointestinal wound healing [19]. Since ERCs
are originated from endometrium which undergoes
menstrual cycle, they are presumed to be capable of sup-
porting angiogenesis and tissue remodeling. Evidence also
shows that ERCs are of great therapeutic effects in the
treatment of critical limb ischemia by stimulating angio-
genesis [21]. Meanwhile, ERCs secrete matrix metallopro-
teases, which is important in tissue remodeling during the
menstruation [28]. Thus, we assume that ERCs mediate
the healing of tissue injury in this experimental colitis
model through the similar tissue repair manner. The re-
lated study on ERCs is currently underway.
Interestingly, ERCs derived from human menstrual
blood are tolerated and exhibit therapeutic effects on
colitis in the immune-competent mice. The immunosup-
pressive effect of ERCs might have different mechanisms
in xenogeneic settings as compared to those of allogen-
eic settings. However, we did find the immunoregulatory
effects of ERCs in this experimental colitis xenogeneic
model, implying that, in addition to their potential effects
in angiogenesis, xenogeneic ERCs could play an important
role in regulating immune responses against colitis in
mice. This notion is supported by the reports that human
umbilical cord blood MSCs reduced colitis in mice [61],
and that human ERCs were able to suppress cell prolifera-
tion, IFN-γ and TNF-α production in a mouse mixed
lymphocyte reaction [21]. This finding further supports
the immune privilege property of ERCs and the possibility
of utilization of allogeneic ERCs to treat UC in the clinical
settings.
Although ERC-based cell therapy proves to be effective
in attenuation of colitis, the precise mechanisms are not
fully understood. For an instance, few data of the im-
planted sites of ERCs is recorded and the mechanism of
homing is still elusive. Since ERCs are mesenchymal-like
stem cells derived from the menstrual blood and express
migration-related marker such as CD44 [62], and based
on the data from our MSC-related publication [63], we
speculate that ERCs could have the similar migration
property as MSCs, and migrate to injured tissue and
lymphoid organ in a similar mechanism in the colitis
mice. Thus, the in-depth studies are warranted to clarify
how ERCs are involved in the procedure.
Conclusions
This study has demonstrated that ERC transplantation is
effective in the treatment of DSS-induced colitis. After
the intravenous administration, ERCs ameliorated the
clinic symptoms and the histological changes in the colons
of DSS-induced colitis in mice. ERCs reduced intra-colon
inflammatory cell infiltration, and modulated the tran-
scriptional levels of inflammatory cytokines, as well as thenumber of immune cells. Moreover, ERCs possess some
advantages in comparison with MSCs from other sources
including the ease of abstraction, considerable availability,
obtaining the cells from a waste tissue and the expandabil-
ity to great quantities without loss of differentiation ability
or karyotypic abnormalities. In the light of their immuno-
modulatory and reparative capacity, ERCs could be a
novel candidate for the treatment of IBD in clinic. This
study serves as the basis for future studies, such as dose
dependence study, toxicity and biocompatibility study. We
suggest further clinical investigation of ERC is warranted.
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